Core Information from the Text:
Here’s a breakdown of the core information from the provided text, organized for clarity:
1. Collaboration & Licensing:
* Partners: UMass Chan Medical School (specifically the lab of Dr. Khvorova and postdoc dr. Hassan Fakih) and PLaN Therapeutics (a nonprofit biotech owned by the PLN Foundation).
* Agreement: PLaN Therapeutics has licensed technology from umass chan to develop a therapy for PLN-R14del cardiomyopathy. PLaN retains exclusive rights.
* Goal: To further develop an allele-specific siRNA-based therapy.
2. Disease Focus: PLN-R14del Cardiomyopathy
* Cause: A dominant genetic mutation in the phospholamban (PLN) gene.
* Effects: Progressive heart failure and life-threatening arrhythmia.
* Current Treatment: General heart failure medication (ineffective at stopping disease progression), ultimately leading to the need for heart transplant.
3. Therapy Approach: Allele-Specific siRNA
* siRNA Basics: Short RNA molecules that silence specific genes by degrading their mRNA, preventing protein production.
* Key Innovation: The therapy targets only the mutated PLN gene, leaving the healthy gene untouched (“allele-specific”).
* Challenges: Delivery to the heart, off-target effects, and chemical durability of siRNA.
* Solution being pursued: Clinically validated chemical modifications to improve durability, distribution, and target engagement.
* Proposed Dosing: Subcutaneous injection approximately every 2-3 months.
4.PLaN Therapeutics
* Type: Nonprofit biotechnology company.
* Origin: Created by the PLN Foundation.
* Mission: Develop disease-modifying therapies for PLN-R14del cardiomyopathy and make them accessible at a fair price.
5. Key Quotes highlighting optimism:
* dr.Fakih: Partnership with PLaN is crucial for translating research into a benefit for patients.
* Pavlina Konstantinova (PLaN CEO): Collaboration is a critical step towards a potential therapy and offers hope to patients.
* Dr. Khvorova: Their technology can deliver siRNA to the heart, a major step towards solving the delivery problem.
Related reading